Tridek One, Paris, June 4, 2019 – Tridek One, a biotech company specialized in the development of products for the treatment of immune disorders, is pleased to announce a first round of funding of 3 million euros with leading investors Advent France Biotechnology and Advent Life Sciences.
“We are very pleased to see our work thus valued through the creation and funding of Tridek-One. This was made feasible with the support of Inserm Transfert, but also two European leading investment funds, Advent France Biotechnoloy and Advent Life Sciences, ” says Dr. Giuseppina Caligiuri, cardiologist and researcher in the INSERM Unit 1148 of the Bichat Hospital in Paris.
“Investing early in seed-type financing, in robust technology and science, is a prerequisite for Advent France Biotechnology team. This strategy is part of our DNA, because beyond the financial means, we are actively involved in the setting-up and structuring of the company alongside the founders, ” says Dr. Alain Huriez, Chairman and General Partner of Advent France Biotechnology.
“We believe this investment will accelerate the company’s preparations for clinical trials of the first CD31 agonist, with the potential to provide safe and effective treatment for inflammatory vascular diseases,” says Dr. Raj Parekh, General Partner of Advent Life Sciences.
Founded in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti, researchers in INSERM Unit 1148, located at Bichat Hospital in Paris, together with Advent France Biotechnology, Tridek-One is developing a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions. For more information, please visit www. tridekone.com/
About Inserm Transfert
Inserm Transfert, founded in 2000, is Inserm’s private subsidiary, which specializes in life sciences technology transfer. Inserm Transfert supports Inserm’s research units and researchers in their efforts to promote their work. Its action is part of the translational continuum from basic and technological research to clinical and applied research for the creation of economic and societal values. For more information, please visit www.inserm-transfert.com
About Advent France Biotechnology
Advent France Biotechnology is a French Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward. The firm works with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and drive inventive Life Sciences start-ups to success. Advent France Biotechnology Seed Fund I stands as the first dedicated Life Sciences seed-fund in France. For more information, please visit www.adventfb.com
About Advent Life Sciences (UK)
Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. The team consists of professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The firm invests in a range of sectors within life sciences, principally in new drug discovery, enabling technologies and med tech. For more information, please visit www.adventls.com
Contact presse :
firstname.lastname@example.org – +33 6 64 18 99 59